KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Long-Term Investments (2023 - 2025)

Biocryst Pharmaceuticals' Long-Term Investments history spans 9 years, with the latest figure at $61.2 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 200.96% year-over-year to $61.2 million; the TTM value through Dec 2025 reached $61.2 million, up 200.96%, while the annual FY2025 figure was $61.2 million, 200.96% up from the prior year.
  • Long-Term Investments reached $61.2 million in Q4 2025 per BCRX's latest filing, up from $39.7 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $64.3 million in Q2 2024 to a low of $3.4 million in Q1 2023.
  • Average Long-Term Investments over 3 years is $26.9 million, with a median of $20.3 million recorded in 2024.
  • Peak YoY movement for Long-Term Investments: surged 1766.97% in 2024, then plummeted 84.29% in 2025.
  • A 3-year view of Long-Term Investments shows it stood at $3.4 million in 2023, then skyrocketed by 489.93% to $20.3 million in 2024, then skyrocketed by 200.96% to $61.2 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Long-Term Investments are $61.2 million (Q4 2025), $39.7 million (Q3 2025), and $10.1 million (Q2 2025).